Roche, the Swiss pharmaceutical leader, has unveiled plans to invest $50 billion in the United States over the next five years. This strategic initiative marks one of the most substantial foreign investments ever made in the U.S. healthcare sector and signals Roche’s long-term commitment to the North American market.